RT Journal Article
SR Electronic
T1 Late Breaking Abstract - Prevalence, characterization and costs of severe asthma in Spain (BRAVO 1)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4639
DO 10.1183/13993003.congress-2020.4639
VO 56
IS suppl 64
A1 Christian Domingo Ribas
A1 Ana Sogo Sagardia
A1 Elena Prina
A1 Antoni Sicras Mainar
A1 Aram Sicras Navarro
A1 Clara Engroba Teijeiro
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/4639.abstract
AB Objectives: To determine the prevalence, comorbidities, biomarkers characterization and costs of severe asthma in patients ≥12-year-old in real life.Methods: Retrospective, cross-sectional, nationwide study that used a top-down approach. Data from BIG-PAC® database (Real Life Data) were used, which is an electronic medical record of 1.9 million Spanish patients (pts) aged ≥12 who had demanded medical care during 2017. Severe asthma (SA) was defined as asthma that required GINA step 5 treatment. Uncontrolled pts were defined by GINA 2019 criteria and oral corticosteroid (OCS) dependent pts were defined by prescription of OCS for at least 6 months. Biomarkers such as blood eosinophils, Fractional Exhaled Nitric Oxide (FeNO) and Immunoglobulin E (IgE) were used to phenotype type 2 pts.Results: The prevalence of asthma was 5.5%. Of these, SA was 7.7%, of whom: 64.1% had uncontrolled SA; 81.2% presented type 2 asthma; 31.2% were OCS-dependent (37% in the uncontrolled SA group); The most common type 2 comorbidities were allergic rhinitis (66.1%), atopic dermatitis (29.1%) and CRSwNP (14.6%). Biologics were administered in 3.8% of total SA patients and 4.3% of patients of the uncontrolled group. The mortality rate was 4.2% and 5.5% in the total SA and the uncontrolled SA group respectively. The total annual costs per patient for uncontrolled SA were 6.010€ and 2.791€ in the controlled SA pts.Conclusions: A vast majority of SA pts present with type-2 asthma. SA continues to have high rates of uncontrolled and OCS dependent asthma despite new available treatments. Uncontrolled SA costs twice as much as controlled pts.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4639.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).